Sunday, 20 May 2018

louis vuitton lover Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH

borse estive louis vuitton Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH

Cannabics Pharmaceuticals Inc. THC, THCA, CBD and CBDA).

These tests are available to cancer patients who send blood samples and receive supportive data for their physicians to optimize and personally tailor their cannabinoid treatment.

SIMFO has already commenced preclinical studies on cannabinoid antitumor activity and drug development utilizing Cannabics Pharmaceuticals’ proprietary cannabinoid formulations.

Dr. Eyal Ballan, Co founder and CTO, said: “We are honored to work hand in hand with SIMFO’s noted scientists and physicians. We believe our collaboration will pave the way for highly effective natural anticancer therapy.”

SIMFO GmbH is a research and development facility that has achieved medical renown expertise in personalized medicine. It focuses particularly on the development of innovative analysis methods in oncological diagnostics to optimize patient specific therapy. SIMFO GmbH supports foreign customers and collaborative partners. The Company’s R is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

Certain statements contained in this release may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10 Q Report filed on April 14th, 2017. We undertake no duty to update any forward looking statement or any information contained in this press release or in other public disclosures at any time.

Certain statements contained in this release may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10 K/A Report filed on March 15, 2017. We undertake no duty to update any forward looking statement or any information contained in this press release or in other public disclosures at any time.
louis vuitton lover Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH